0001193125-23-012744 Sample Contracts

EXECUTIVE EMPLOYMENT AGREEMENT

Executive Employment Agreement • January 23rd, 2023 • CinCor Pharma, Inc. • Pharmaceutical preparations • New York

• Contract Type
  Executive Employment Agreement
• Filed
  January 23rd, 2023
• Company
  CinCor Pharma, Inc.
• Industry
  Pharmaceutical preparations
• Jurisdiction
  New York

This EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) by and between Michael W. Kalb (“Executive”) and CinCor Pharma (the “Company”) is effective as of November 4, 2022 or such earlier or later day that Executive commences employment with the Company by agreement between the Company and Executive (such date that Executive commences employment, the “Effective Date”).

RECIPROCAL CONFIDENTIALITY AGREEMENT

Reciprocal Confidentiality Agreement • January 23rd, 2023 • CinCor Pharma, Inc. • Pharmaceutical preparations • Delaware

• Contract Type
  Reciprocal Confidentiality Agreement
• Filed
  January 23rd, 2023
• Company
  CinCor Pharma, Inc.
• Industry
  Pharmaceutical preparations
• Jurisdiction
  Delaware

This Reciprocal Confidentiality Agreement (this “Agreement”) is made effective as of May 10, 2021 (the “Effective Date”), by and between AstraZeneca Pharmaceuticals LP, a Delaware limited partnership with offices at 1800 Concord Pike, Wilmington, Delaware 19803 (“AstraZeneca”) and CinCor Pharma, Inc, a corporation with offices at 5375 Medpace Way, Cincinnati OH 45227 (the “Company”), (each a “Party”) (collectively, the “Parties”)

HIGHLY CONFIDENTIAL January 6, 2023 Mason Freeman Re: Retention Bonus Agreement Dear Mason:

Retention Bonus Agreement • January 23rd, 2023 • CinCor Pharma, Inc. • Pharmaceutical preparations

• Contract Type
  Retention Bonus Agreement
• Filed
  January 23rd, 2023
• Company
  CinCor Pharma, Inc.
• Industry
  Pharmaceutical preparations

CinCor Pharma, Inc. (“the Company”) seeks to incentivize you to continue to contribute to the Company’s goal of achieving its business goals. As you may know, the Company is pursuing an acquisition by a subsidiary of AstraZeneca Inc. (“Parent”) (such transaction, the “Merger”), pursuant to the terms of an Agreement and Plan of Merger between Parent, the Company, and certain other parties (the “Merger Agreement”). In order to reward your contributions to the Company and to encourage your continued efforts to the combined organization for a retention period following the consummation of the Merger (the “Closing”), the Company hereby offers you the opportunity to receive a bonus as specified below, subject to the terms and conditions of this letter agreement (the “Agreement”). This Agreement shall become effective as of the Closing and is conditioned on the occurrence of the Closing.